In June 2026, Gilead Sciences and Lakefront Biotherapeutics jointly completed the acquisition of Ouro Medicines, a deal announced in March 2026 and finalized by June 4, 2026. The transaction centered on gamgertamig (OM336), a clinical-stage BCMAxCD3 bispecific T-cell engager being developed for autoimmune diseases.